178 related articles for article (PubMed ID: 24339940)
1. A fluorescence-based thermal shift assay identifies inhibitors of mitogen activated protein kinase kinase 4.
Krishna SN; Luan CH; Mishra RK; Xu L; Scheidt KA; Anderson WF; Bergan RC
PLoS One; 2013; 8(12):e81504. PubMed ID: 24339940
[TBL] [Abstract][Full Text] [Related]
2. Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis.
Pavese JM; Ogden IM; Voll EA; Huang X; Xu L; Jovanovic B; Bergan RC
PLoS One; 2014; 9(7):e102289. PubMed ID: 25019290
[TBL] [Abstract][Full Text] [Related]
3. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
4. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Gao Y; Davies SP; Augustin M; Woodward A; Patel UA; Kovelman R; Harvey KJ
Biochem J; 2013 Apr; 451(2):313-28. PubMed ID: 23398362
[TBL] [Abstract][Full Text] [Related]
5. Ligand efficiency based approach for efficient virtual screening of compound libraries.
Ke YY; Coumar MS; Shiao HY; Wang WC; Chen CW; Song JS; Chen CH; Lin WH; Wu SH; Hsu JT; Chang CM; Hsieh HP
Eur J Med Chem; 2014 Aug; 83():226-35. PubMed ID: 24960626
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of novel fluorescently labeled analogs of vemurafenib targeting MKK4.
Kircher T; Pantsar T; Oder A; Peter von Kries J; Juchum M; Pfaffenrot B; Kloevekorn P; Albrecht W; Selig R; Laufer S
Eur J Med Chem; 2021 Jan; 209():112901. PubMed ID: 33092905
[TBL] [Abstract][Full Text] [Related]
7. From Enzyme to Whole Blood: Sequential Screening Procedure for Identification and Evaluation of p38 MAPK Inhibitors.
Bauer SM; Kubiak JM; Rothbauer U; Laufer S
Methods Mol Biol; 2016; 1360():123-48. PubMed ID: 26501907
[TBL] [Abstract][Full Text] [Related]
8. A high-throughput, nonisotopic, competitive binding assay for kinases using nonselective inhibitor probes (ED-NSIP).
Vainshtein I; Silveria S; Kaul P; Rouhani R; Eglen RM; Wang J
J Biomol Screen; 2002 Dec; 7(6):507-14. PubMed ID: 14599348
[TBL] [Abstract][Full Text] [Related]
9. Fluorescence labels in kinases: a high-throughput kinase binding assay for the identification of DFG-out binding ligands.
Simard JR; Rauh D
Methods Mol Biol; 2012; 800():95-117. PubMed ID: 21964785
[TBL] [Abstract][Full Text] [Related]
10. FLiK: a direct-binding assay for the identification and kinetic characterization of stabilizers of inactive kinase conformations.
Simard JR; Rauh D
Methods Enzymol; 2014; 548():147-71. PubMed ID: 25399645
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors.
Deibler KK; Schiltz GE; Clutter MR; Mishra RK; Vagadia PP; O'Connor M; George MD; Gordon R; Fowler G; Bergan R; Scheidt KA
ChemMedChem; 2019 Mar; 14(6):615-620. PubMed ID: 30707493
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel scaffolds for Rho kinase 2 inhibitor through TRFRET-based high throughput screening assay.
Oh KS; Mun J; Cho JE; Lee S; Yi KY; Lim CJ; Lee JS; Park WJ; Lee BH
Comb Chem High Throughput Screen; 2013 Jan; 16(1):37-46. PubMed ID: 22934984
[TBL] [Abstract][Full Text] [Related]
13. Discovery and Characterization of a Biologically Active Non-ATP-Competitive p38 MAP Kinase Inhibitor.
Wilson BA; Alam MS; Guszczynski T; Jakob M; Shenoy SR; Mitchell CA; Goncharova EI; Evans JR; Wipf P; Liu G; Ashwell JD; O'Keefe BR
J Biomol Screen; 2016 Mar; 21(3):277-89. PubMed ID: 26538432
[TBL] [Abstract][Full Text] [Related]
14. A new prognosis prediction model combining TNM stage with MAP2K4 and JNK in postoperative pancreatic cancer patients.
Liu XD; Zhang ZW; Wu HW; Liang ZY
Pathol Res Pract; 2021 Jan; 217():153313. PubMed ID: 33341545
[TBL] [Abstract][Full Text] [Related]
15. A combinatorial biophysical approach; FTSA and SPR for identifying small molecule ligands and PAINs.
Redhead M; Satchell R; Morkūnaitė V; Swift D; Petrauskas V; Golding E; Onions S; Matulis D; Unitt J
Anal Biochem; 2015 Jun; 479():63-73. PubMed ID: 25837771
[TBL] [Abstract][Full Text] [Related]
16. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel TAOK2 inhibitor scaffolds from high-throughput screening.
Piala AT; Akella R; Potts MB; Dudics-Giagnocavo SA; He H; Wei S; White MA; Posner BA; Goldsmith EJ
Bioorg Med Chem Lett; 2016 Aug; 26(16):3923-7. PubMed ID: 27426302
[TBL] [Abstract][Full Text] [Related]
18. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
Coussens NP; Kales SC; Henderson MJ; Lee OW; Horiuchi KY; Wang Y; Chen Q; Kuznetsova E; Wu J; Chakka S; Cheff DM; Cheng KC; Shinn P; Brimacombe KR; Shen M; Simeonov A; Lal-Nag M; Ma H; Jadhav A; Hall MD
J Biol Chem; 2018 Aug; 293(35):13750-13765. PubMed ID: 29945974
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Iterative Screening with Stepwise Compound Selection Based on Novartis In-house HTS Data.
Paricharak S; IJzerman AP; Bender A; Nigsch F
ACS Chem Biol; 2016 May; 11(5):1255-64. PubMed ID: 26878899
[TBL] [Abstract][Full Text] [Related]
20. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha.
Simard JR; Grütter C; Pawar V; Aust B; Wolf A; Rabiller M; Wulfert S; Robubi A; Klüter S; Ottmann C; Rauh D
J Am Chem Soc; 2009 Dec; 131(51):18478-88. PubMed ID: 19950957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
